title: Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.
authors.affiliation: Department of Pediatrics, University of Missouri Kansas City-School of Medicine, Kansas City, MO, USA.
authors.forename: M
authors.initials: M
authors.lastname: Brown
authors.affiliation: Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
authors.forename: D
authors.initials: D
authors.lastname: Myers
authors.affiliation: Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
authors.forename: N
authors.initials: N
authors.lastname: Shreve
authors.affiliation: Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
authors.forename: R
authors.initials: R
authors.lastname: Rahmetullah
authors.affiliation: Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
authors.forename: M
authors.initials: M
authors.lastname: Radhi
mesh_terms: D000074323:Alemtuzumab / Q000008:administration & dosage*; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D036101:Cord Blood Stem Cell Transplantation; D003520:Cyclophosphamide / Q000008:administration & dosage*; D019871:Dyskeratosis Congenita / Q000628:therapy*; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006579:Heterozygote; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D009154:Mutation; D019172:Transplantation Conditioning / Q000379:methods*; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D051598:Whole Body Imaging
chemical_list: D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine